baht or 6. 56 percent from the previous year, mainly due to a decrease of drug and medical supply cost since the volume of general patients and social security patients decreased. Besides, the Company
orders by significantly concern customer safety. The Company still provides necessary services for such as supermarket, convenience stores, banks, drug stores, food and beverages shops for take away and
) Derivatives, each coming with its own strong market position. The acquisition comes with its own strong R&D and technical capabilities apart from portfolio of about 900 patents and other intellectual properties
system of new medicines according to the additional standards SET forth by the Food and Drug administration. Therefore, it is necessary to use the capital to proceed the project amount 32,000,000 baht
Constructions (2) Registration of 100 drugs formulas (54 formulas for human medicine and 46 formulas for animals) owned by the seller (3) Registration of special drug formulas, consisting of 12 formulas including
and Drug Administration (CFDA), which took around 2 months, that we have got CFDA in early 2018. Sales by product category Consolidated financial statements For the three months period ended March 31
cause of change as follow: 1. Sales Revenue decreased by 139.64 million baht or 7.49% from 1,863.61 million baht in 2018 to 1,723.97 million baht in 2019 due to sales volume decrease, from strong
strong appreciation of THB/USD, which strengthened from the average rate of Baht 34.2863/USD in Q2-17 to Baht 31.9468/USD in the same period this year. Sales revenues of this quarter amounted to Baht
noteworthy endeavor was the production of a short film featuring Prof. Dr. Krisana Kraisintu’s trip to Congo to disseminate knowledge on formulating an HIV “cocktail” drug, which was broadcast via online media
business which comprised of 81.22% of sale and service income in Q3 2021 remained strong and grew in line with the industry. In Thailand, customer orders were slightly slower than planned but still higher